Nandini Piramal

About

For Nandini Piramal, FY25 marked a key milestone: Piramal Pharma Ltd crossed $1 billion in revenue—a feat that caps a 15-year journey which began when the Ajay Piramal-led group sold its domestic formulations business to Abbott for $3.72 billion in 2010. What remained was a lean but promising portfolio. When Nandini joined the family business in 2003, she was tasked with building that consumer healthcare arm. Alongside, she took on group-level roles spanning HR, IT, and strategy. A steady, disciplined scale-up followed. From just three brands and ₹100 crore in revenue in 2008, the consumer health business grew into a 25+ brand portfolio with nearly ₹1,000 crore in sales by 2024. Her role expanded after a group restructuring led to Piramal Pharma’s listing in October 2022, following which she took charge as the chairperson. “The last three years have been about building a resilient and future-ready organisation, rather than just chasing near-term growth,” says Nandini. “Our focus has been on bringing clarity to each of our businesses, strengthening our operating model, and investing in areas that would define long-term value creation.” Now, she is setting her sights on the next leap: doubling revenues to $2 billion and positioning Piramal Pharma among the Top 10 companies globally in its addressable markets by FY30.